Selected article for: "acute SARS respiratory distress syndrome and respiratory distress syndrome"

Author: Yueping Li; Zhiwei Xie; Weiyin Lin; Weiping Cai; Chunyan Wen; Yujuan Guan; Xiaoneng Mo; Jian Wang; Yaping Wang; Ping Peng; Xudan Chen; Wenxin Hong; Guangming Xiao; Jinxin Liu; Lieguang Zhang; Fengyu Hu; Feng Li; Feng Li; Fuchun Zhang; Xilong Deng; Linghua Li
Title: An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI)
  • Document date: 2020_3_23
  • ID: 9hknw4ws_4
    Snippet: Additionally, despite lacking a valid estimate of efficacy, the combination of LPV/r has been associated with significantly fewer adverse clinical outcomes (acute respiratory distress syndrome or death) in 41 patients with SARS compared with ribavirin alone in 111 historical controls (2.4% versus 28.8%, P= 0.001) in the 21 days after the onset of symptoms [ 9 ] . Thus, based on in vitro testing and previous clinical trials demonstrating its effic.....
    Document: Additionally, despite lacking a valid estimate of efficacy, the combination of LPV/r has been associated with significantly fewer adverse clinical outcomes (acute respiratory distress syndrome or death) in 41 patients with SARS compared with ribavirin alone in 111 historical controls (2.4% versus 28.8%, P= 0.001) in the 21 days after the onset of symptoms [ 9 ] . Thus, based on in vitro testing and previous clinical trials demonstrating its efficacy against other coronaviruses, LPV/r was regarded as an option for treating COVID-19.

    Search related documents:
    Co phrase search for related documents